ECSP11011222A - Règimen de dosificaciòn para un agonista de los receptores de s1p - Google Patents

Règimen de dosificaciòn para un agonista de los receptores de s1p

Info

Publication number
ECSP11011222A
ECSP11011222A EC2011011222A ECSP11011222A ECSP11011222A EC SP11011222 A ECSP11011222 A EC SP11011222A EC 2011011222 A EC2011011222 A EC 2011011222A EC SP11011222 A ECSP11011222 A EC SP11011222A EC SP11011222 A ECSP11011222 A EC SP11011222A
Authority
EC
Ecuador
Prior art keywords
dosage scheme
dosage
receiver agonist
agonist
receiver
Prior art date
Application number
EC2011011222A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011222(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011222A publication Critical patent/ECSP11011222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los modulares o agonistas de los receptores de S1P se administran siguiendo un règimen de dosificaciòn en donde, durante los dias iniciales del tratamiento, la dosificaciòn diaria es màs baja que la dosificaciòn diaria convencional.
EC2011011222A 2008-12-22 2011-06-22 Règimen de dosificaciòn para un agonista de los receptores de s1p ECSP11011222A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
ECSP11011222A true ECSP11011222A (es) 2011-08-31

Family

ID=41667217

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011222A ECSP11011222A (es) 2008-12-22 2011-06-22 Règimen de dosificaciòn para un agonista de los receptores de s1p

Country Status (43)

Country Link
US (12) US20110257133A1 (es)
EP (7) EP3120844A1 (es)
JP (7) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (5) CY1116990T1 (es)
DK (4) DK3453387T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (4) ES2810823T3 (es)
FI (2) FI4098256T3 (es)
FR (2) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (4) HRP20151190T1 (es)
HU (6) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (5) LT3453387T (es)
LU (1) LUC00183I2 (es)
MA (1) MA32981B1 (es)
ME (2) ME03594B (es)
MX (3) MX2011006623A (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (4) PL3453387T3 (es)
PT (4) PT3453387T (es)
RS (3) RS66784B9 (es)
SG (1) SG171404A1 (es)
SI (4) SI2379067T1 (es)
SM (2) SMT202000441T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033168T2 (en) 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosage regimen for selective SIP1 receptor agonist
RS66784B9 (sr) 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
TW201320994A (zh) * 2011-10-11 2013-06-01 Novartis Ag 投藥療程
MX350891B (es) 2012-08-17 2017-09-22 Actelion Pharmaceuticals Ltd Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso.
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
MX386419B (es) * 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
JP7850669B2 (ja) * 2020-02-28 2026-04-23 アカール・ファーマ・プロプライエタリー・リミテッド Ｓ１ｐ受容体調節物質
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US10080481B2 (en) * 2005-02-10 2018-09-25 G.I. View Ltd. Advancement techniques for gastrointestinal tool with guiding element
AU2008310846C1 (en) * 2007-10-12 2022-10-06 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
HUE033168T2 (en) * 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosage regimen for selective SIP1 receptor agonist
KR20110020928A (ko) * 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
CN105213372A (zh) 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
RS66784B9 (sr) 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora

Also Published As

Publication number Publication date
SMT202000054T1 (it) 2020-03-13
HRP20201167T1 (hr) 2020-12-11
CY1122812T1 (el) 2021-05-05
EP4098256B1 (en) 2025-02-26
HUE052048T2 (hu) 2021-04-28
EP2379067B1 (en) 2015-09-02
JP2017141238A (ja) 2017-08-17
LTPA2025520I1 (es) 2025-06-25
HN2011001759A (es) 2013-11-26
US20200330407A1 (en) 2020-10-22
FR25C1012I1 (fr) 2025-06-13
US20110257133A1 (en) 2011-10-20
LT3453387T (lt) 2020-08-25
JP2016135752A (ja) 2016-07-28
US20250262171A1 (en) 2025-08-21
CL2013001558A1 (es) 2013-10-25
EP3409274A1 (en) 2018-12-05
MX2011006623A (es) 2011-07-12
RS66784B9 (sr) 2025-08-29
JP2019167360A (ja) 2019-10-03
FIC20253002I1 (fi) 2025-05-23
PT3453387T (pt) 2020-08-11
ZA201205942B (en) 2013-03-27
SI4098256T1 (sl) 2025-06-30
EP3409274B1 (en) 2019-11-20
PE20120337A1 (es) 2012-04-24
ME03594B (me) 2020-07-20
DK3453387T3 (da) 2020-08-10
DK4098256T3 (da) 2025-04-22
TN2011000272A1 (en) 2012-12-17
AU2009330176A1 (en) 2011-07-07
EP4098256B9 (en) 2025-06-18
EA201100978A1 (ru) 2012-01-30
LTPA2020005I1 (lt) 2020-12-10
HRP20151190T1 (hr) 2016-01-01
RS59857B1 (sr) 2020-02-28
EP3453387A1 (en) 2019-03-13
JP2014144970A (ja) 2014-08-14
ES2552823T3 (es) 2015-12-02
US20140148415A1 (en) 2014-05-29
HUE048717T4 (hu) 2022-02-28
ES2760607T3 (es) 2020-05-14
SI3453387T1 (sl) 2020-10-30
FR20C1060I1 (fr) 2020-12-25
PL4098256T3 (pl) 2025-06-09
NO2020038I1 (no) 2020-11-18
PT3409274T (pt) 2019-12-17
EP4098256A1 (en) 2022-12-07
SG171404A1 (en) 2011-07-28
ZA201103863B (en) 2012-10-31
HUE071189T2 (hu) 2025-08-28
CR20110274A (es) 2011-07-19
JP7329965B2 (ja) 2023-08-21
DK2379067T3 (en) 2015-12-07
US20190091180A1 (en) 2019-03-28
CY1123255T1 (el) 2021-10-29
SI3409274T1 (sl) 2020-03-31
NZ593065A (en) 2012-11-30
TW201028143A (en) 2010-08-01
MA32981B1 (fr) 2012-01-02
LUC00183I2 (es) 2024-07-01
WO2010075239A1 (en) 2010-07-01
CA2747802C (en) 2021-02-09
PT4098256T (pt) 2025-04-10
US20180289638A1 (en) 2018-10-11
IL274756A (en) 2020-07-30
AU2009330176C9 (en) 2017-01-05
EP3120844A1 (en) 2017-01-25
CY2020036I1 (el) 2021-03-12
AU2009330176B2 (en) 2014-03-06
LT4098256T (lt) 2025-06-10
MX2021010759A (es) 2022-07-19
PL3453387T3 (pl) 2020-11-02
AR074826A1 (es) 2011-02-16
CU20110136A7 (es) 2012-01-31
RS60666B1 (sr) 2020-09-30
PL3409274T3 (pl) 2020-06-01
ES2810823T3 (es) 2021-03-09
MX385959B (es) 2025-03-18
US20100160259A1 (en) 2010-06-24
CO6390117A2 (es) 2012-02-29
JP2012513401A (ja) 2012-06-14
HUS2000046I1 (hu) 2020-12-28
US20160081949A1 (en) 2016-03-24
CY2025012I1 (el) 2026-02-25
KR20110096175A (ko) 2011-08-29
SMT202000441T1 (it) 2020-09-10
CA2747802A1 (en) 2010-07-01
EP2907511A1 (en) 2015-08-19
KR101347919B1 (ko) 2014-01-07
PL2379067T3 (pl) 2016-02-29
CY1116990T1 (el) 2017-04-05
US20140066657A1 (en) 2014-03-06
DK4098256T5 (da) 2025-07-21
CN102264359A (zh) 2011-11-30
HUE026869T2 (en) 2016-08-29
HRP20192175T1 (hr) 2020-03-20
US20170189353A1 (en) 2017-07-06
IL278914A (en) 2021-01-31
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
FI4098256T3 (fi) 2025-03-31
CL2011001529A1 (es) 2012-02-24
EP3453387B1 (en) 2020-06-03
PT2379067E (pt) 2015-12-23
RS66784B1 (sr) 2025-06-30
CY2020036I2 (el) 2021-06-25
HRP20250568T1 (hr) 2025-07-04
AU2009330176C1 (en) 2016-12-08
US20160263061A1 (en) 2016-09-15
ES3017254T3 (en) 2025-05-12
JP2022103194A (ja) 2022-07-07
CY2025012I2 (el) 2026-02-25
HUE048717T2 (hu) 2020-08-28
ME03802B (me) 2021-04-20
HUS2500026I1 (hu) 2025-07-28
EP2379067A1 (en) 2011-10-26
IL213170A0 (en) 2011-07-31
SI2379067T1 (sl) 2016-01-29
DK3409274T3 (da) 2019-12-16
UY32352A (es) 2010-07-30
JP2024129030A (ja) 2024-09-26
BRPI0923500A2 (pt) 2018-05-29
EP3677260A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
ECSP11011222A (es) Règimen de dosificaciòn para un agonista de los receptores de s1p
MX2011006625A (es) Regimen de dosificacion de un agonista de los receptores de s1p.
EA201000046A1 (ru) Замещенные имидазогетероциклы
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
UY32853A (es) Nuevos compuestos de oxadiazol
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
MX341849B (es) Nitrilos espirociclicos como inhibidores de proteasa.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
CL2011000138A1 (es) Uso de compuestos acido 1-{4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxiimino)-etil-2-etil-bencil}-azetidin-3-carboxilico para la preparacion de un medicamento para prevenir, inhibir o tratar una condicion inflamatoria seleccionada de polimiositis o dermatomiositis.
MX2021015873A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
UY32414A (es) Nuevos metodos
UY31824A (es) Nuevos compuestos
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
CR11188A (es) Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
AR061139A1 (es) Tratamiento de los calores subitos con antagonistas del receptor muscarinico
AR062306A1 (es) Milnacipran para el rtamiento de disfuncion cognoscitiva asociada con fibromalgia
AR062307A1 (es) Milnacipran parel tratamiento de fatigas asociadas con el sindrome de fibromalgia
UY29630A1 (es) Metodos y formas de dosificación para reducir los efectos secundarios de compuestos de carbamato